Stock Events

Stock Events

PolyPeptide Group 

$35.39
5
+$3.89+12.35% Monday 13:30

Statistics

Day High
35.39
Day Low
35.39
52W High
39.4
52W Low
31.5
Volume
476
Avg. Volume
27
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 22
$0.31
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MarExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.94
-0.51
-0.09
0.34
Expected EPS
0.3406079
Actual EPS
N/A

Financials

-5.83%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
702.12MRevenue
-40.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PLYGF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bank of China
BACHF
Mkt Cap235.57B
Bachem Holding AG specializes in peptide technology, directly competing in the same sector as PolyPeptide.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. develops peptide therapeutics among other biotech solutions, overlapping with PolyPeptide's market.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company, through its acquisition of Prevail Therapeutics, competes in peptide drug development.
Novartis
NVS
Mkt Cap237.61B
Novartis AG engages in significant research in peptide-based drugs, competing for similar market share.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has investments in peptide research and drug development, positioning it as a competitor.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG develops peptide therapeutics, directly competing with PolyPeptide in the biopharmaceutical field.
Sanofi
SNY
Mkt Cap124.45B
Sanofi SA focuses on peptide drug solutions among its diverse biopharmaceutical products, competing with PolyPeptide.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a strong focus on innovative drug development including peptides, competing in the same arena.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc invests in peptide-based drug development, making it a competitor in this specialized field.

About

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Show more...
CEO
Country
CH
ISIN
CH1110760852

Listings

F
DE
8H0.F
LSE
GB
0AAJ.LSE
SW
CH
PPGN.SW
OTC Link
US
PLYGF

0 Comments

Share your thoughts

FAQ

What is PolyPeptide Group stock price today?▼
The current price of PLYGF is $35.39 USD — it has increased by +12.35% in the past 24 hours. Watch PolyPeptide Group stock price performance more closely on the chart.
What is PolyPeptide Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PolyPeptide Group stocks are traded under the ticker PLYGF.
When is the next PolyPeptide Group earnings date?▼
PolyPeptide Group is going to release the next earnings report on August 13, 2026.
What is PolyPeptide Group revenue for the last year?▼
PolyPeptide Group revenue for the last year amounts to 702.12M USD.
What is PolyPeptide Group net income for the last year?▼
PLYGF net income for the last year is -40.91M USD.
Does PolyPeptide Group pay dividends?▼
Yes, PLYGF dividends are paid en. The last dividend per share was 0.31 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is PolyPeptide Group located?▼
PolyPeptide Group operates in the Professional, Scientific, and Technical Services sector.
When did PolyPeptide Group complete a stock split?▼
PolyPeptide Group has not had any recent stock splits.